The RXR agonist LG100268 causes hepatomegaly, improves glycaemic control and decreases cardiovascular risk and cachexia in diabetic mice suffering from pancreatic beta-cell dysfunction

Diabetologia

Volumn 42, Issue 5, 1999, Pages 545-554

  Lenhard, J M ^a   Lancaster, M E ^a   Paulik, M A ^a   Weiel, J E ^a   Binz, J G ^a   Sundseth, S S ^a   Gaskill, B A ^a   Lightfoot, R M ^a   Brown, H R ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Cachexia; Cardiovascular; Diabetes; Dyslipidemia; Hepatomegaly; Islets; PPAR ; RXR

Indexed keywords

6 [1 (5,6,7,8 TETRAHYDRO 3,5,5,8,8 PENTAMETHYL 2 NAPHTHYL)CYCLOPROPYL]NICOTINIC ACID; ALKALINE PHOSPHATASE; ANTIDIABETIC AGENT; FATTY ACID; FIBRINOGEN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; LAURIC ACID; N (2 BENZOYLPHENYL) O [2 (METHYL 2 PYRIDINYLAMINO)ETHYL]TYROSINE; OXYGENASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; ROSIGLITAZONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BROWN ADIPOSE TISSUE; CACHEXIA; CONTROLLED STUDY; DIABETES MELLITUS; FIBRINOGEN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEPATOMEGALY; HYPOLIPEMIA; INSULIN BLOOD LEVEL; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PANCREAS ISLET BETA CELL; PANCREAS ISLET DISEASE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ANIMALS; BLOOD GLUCOSE; CACHEXIA; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; FIBRINOGEN; HEMOGLOBIN A, GLYCOSYLATED; HEPATOMEGALY; HYPERINSULINISM; ISLETS OF LANGERHANS; LIPIDS; LIVER; MALE; MICE; MICE, INBRED C57BL; NICOTINIC ACIDS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; RISK FACTORS; TETRAHYDRONAPHTHALENES; TRANSCRIPTION FACTORS;

EID: 0032966295     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051193     Document Type: Article

References (40)

1. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM (1994) mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 8: 1224-1234
2. Spiegelman BM (1997) Peroxisome proliferator-activated receptor gamma: a key regulator of adipogenesis and systemic insulin sensitivity. Eur J Med Res 2: 457-464
3. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA (1995) An antidiabetic thiazol-idinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270: 12953-12956
4. Lenhard JM, Kliewer SA, Paulik MA, Plunket KD, Lehmann JM, Weiel JE (1997) Effects of troglitazone and metformin on glucose and lipid metabolism: alterations of two distinct molecular pathways. Biochem Pharmacol 54: 801-808
5. Henke BR, Blanchard SG, Brackeen MF et al. (1998) N-(2-Benzoyl-phenyl)-(L)-tyrosine PPARγ agonists (1). Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J Med Chem 41: 5020-5036
6. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H (1988) Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37: 1549-1558
7. Oakes ND, Kennedy CJ, Jenkins AB, Laybutt DR, Chisholm DJ, Kraegen EW (1994) A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 43: 1203-1210
8. de Souza CJ, Yu JH, Robinson DD, Ulrich RG, Meglasson MD (1995) Insulin secretory defect in Zucker fa/fa rats is improved by ameliorating insulin resistance. Diabetes 44: 984-991
9. Mukherjee R, Davies PJ, Crombie DL et al. (1997) Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 386: 407-410
10. Mukherjee R, Strasser J, Jow L, Hoener P, Paterniti JR Jr, Heyman RA (1998) RXR agonists activate PPARalpha-inducible genes, lower triglycerides, and raise HDL levels in vivo. Arterioscler Thromb Vasc Biol 18: 272-276
11. Hummel KP, Coleman DL, Lane PW (1972) The influence of genetic background on expression of mutations at the diabetes locus in the mouse. I. C57BL-KsJ and C57BL-6J strains. Biochem Genet 7: 1-13
12. Shafrir, E (1990) Diabetes in animals. In: Rifkin H, Porte D Jr (eds) Diabetes Mellitus, Theory and Practice. Elsevier, New York, pp 299-340
13. Berkowitz K, Peters R, Kjos SL et al. (1996) Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM. Diabetes 45: 1572-1579
14. Shimabukuro M, Zhou YT, Lee Y, Unger RH (1998) Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J Biol Chem 273: 3547-3550
15. Oosting JD, Hoffmann JJ (1997) Evaluation of an automated photometric fibrinogen assay. Blood Coagul Fibrinolysis 8: 321-326
16. McKenna MC, Robison WG Jr, Bieri JG (1983) Cellular localization of liver vitamin A in rats given total parenteral nutrition (TPN) solutions intravenously or orally. J Nutr 113: 1176-1186
17. Bozzola JJ and Russell LD (1992) In: Bozzola JJ, Russell LD (eds) Electron Microscopy Principles and Techniques for Biologists. Jones and Bartlett Publishers, London, pp 64-182
18. Romano MC, Straub KM, Yodis LA, Eckardt RD. Newton JF (1988) Determination of microsomal lauric acid hydroxylase activity by HPLC with flow-through radiochemical quantitation. Analytical Biochemistry 170: 83-93
19. Paulik MA, Lenhard JM (1997) Thiazolidinediones inhibit alkaline phosphatase activity while increasing expression of uncoupling protein, deiodinase, and increasing mitochondrial mass in C3H10T1/2 cells. Cell Tissue Res 290: 79-87
20. Tai TAC, Jennermann C, Brown KK et al. (1996) Activation of the nuclear receptor peroxisome proliferator-activated receptor gamma promotes brown adipocyte differentiation. J Biol Chem 271: 29909-29914
21. el-Hassan AY, Ibrahim EM, al-Mulhim FA, Nabhan AA, Chammas MY (1992) Fatty infiltration of the liver: analysis of prevalence, radiological and clinical features and influence on patient management. Br J Radiol 65: 774-778
22. Lee SS, Pineau T, Drago J et al. (1995) Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 15: 3012-3022
23. Aldridge TC, Tugwood JD, Green S (1995) Identification and characterization of DNA elements implicated in the regulation of CYP4A1 transcription. Biochem J 306: 473-479
24. Inzucchi SE, Maggs DG, Spollett GR et al. (1998) Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 338: 867-872
25. Burant CF, Sreenan S, Hirano K et al. (1997) Troglitazone action is independent of adipose tissue. Clin Invest 100: 2900-2908
26. Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J (1994) Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb Vasc Biol 14: 54-59
27. Nicodeme E, Nicaud M, Issandou M (1995) Retinoids stimulate fibrinogen production both in vitro (hepatocytes) and in vivo. Induction requires activation of the retinoid X receptor. Arterioscler Thromb Vasc Biol 15: 1660-1667
28. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA (1997) Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272: 3406-3410
29. Schror K (1995) Antiplatelet drugs. A comparative review. Drugs 50: 7-28
30. Ghazzi MN, Perez JE, Antonucci TK et al. (1997) Cardiac and glycemic benefits of troglitazone treatment in NID-DM. The Troglitazone Study Group. Diabetes 46: 433-439
31. Cominacini L, Garbin U, Fratta Pasini A et al. (1998) Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients. Diabetes 47: 130-133
32. Fonseca VA, Reynolds T, Hemphill D et al. (1998) Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complications 12: 181-186
33. Alegret M, Ferrando R, Vazquez M, Adzet T, Merlos M, Laguna JC (1994) Relationship between plasma lipids and palmitoyl-CoA hydrolase and synthetase activities with peroxisomal proliferation in rats treated with fibrates. Br J Pharmacol 112: 551-556
34. Keller H, Dreyer C, Medin J, Mahfoudi A, Ozato K, Wahli W (1993) Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci USA 90: 2160-2164
35. Standeven AM, Escobar M, Beard RL, Yuan YD, Chandraratna RA (1997) Mitogenic effect of retinoid X receptor agonists in rat liver. Biochem Pharmacol 54: 517-524
36. Standeven AM, Beard RL, Johnson AT, Boehm MF, Escobar M, Heyman RA, Chandraratna RA (1996) Retinoid-induced hypertriglyceridemia in rats is mediated by retinoic acid receptors. Fundam Appl Toxicol 33: 264-271
37. Rabelo R, Camirand A, Silva JE (1997) 3′,5′-cyclic adenosine monophosphate-response sequences of the uncoupling protein gene are sequentially recruited during darglitazone-induced brown adipocyte differentiation. Endocrinology 138: 5325-5332
38. D'Costa DF, Price DE, Burden AC (1992) Diabetic neuropathic cachexia associated with malabsorption. Diabet Med 9: 203-205
39. Marcelli D, Spotti D, Conte F et al. (1995) Prognosis of diabetic patients on dialysis: analysis of Lombardy Registry data. Nephrol Dial Transplant 10: 1895-1900
40. Paulik, MA, Buckholz RG, Lancaster ME et al. (1998) Development of infrared imaging to measure thermogenesis in cell culture: Thermogenic effects of Uncoupling protein-2, Troglitazone, and β-adrenoceptor agonists. Pharmaceutical Research 15: 944-949